Tucatinib Approved for PBS Listing, Offering $4,500 Monthly Savings for Metastatic Breast Cancer Patients
Key Insights
The Pharmaceutical Benefits Advisory Committee (search) has recommended tucatinib (Tukysa) for PBS listing, providing affordable access to patients with HER2-positive metastatic breast cancer (search) who previously faced costs exceeding $4,500 per month.
Tucatinib offers an effective treatment option for patients after progression on multiple HER2 (search)-directed therapies, particularly benefiting those with brain metastases (search) who have limited therapeutic alternatives.
Once listed on the PBS, patients will pay approximately $35 monthly instead of the current $4,500, removing significant financial barriers that forced patients to choose between extending their lives and financial stability.
The Pharmaceutical Benefits Advisory Committee (search) (PBAC) has recommended tucatinib (Tukysa) for listing on the Pharmaceutical Benefits Scheme (PBS), marking a significant breakthrough for Australians living with HER2-positive metastatic breast cancer (search). The decision will provide life-saving relief to patients who have been facing impossible financial barriers, with private costs exceeding $4,500 per cycle.
Financial Relief for Patients with Brain Metastases
For patients like Melbourne mother Larissa King, the PBS listing represents hope and financial salvation. King, a mother of three who discovered her breast cancer (search) had spread to her brain earlier this year, currently pays $4,500 monthly for a single bottle of tucatinib that lasts just one month. "I couldn't imagine the future of having to pay that amount regularly," King said.
The financial burden has been overwhelming for King's family. "I've managed to use some of my life insurance... [and] my sister set up a GoFundMe page to help me with one round," she admitted, describing the stress of accessing this crucial medication.
Once tucatinib is listed on the PBS, patients will only pay around $35 per month, representing savings of more than $4,500 monthly. This dramatic cost reduction will eliminate the impossible choice many patients currently face between extending their lives and financial stability.
Critical Treatment for Aggressive Cancer
Tucatinib provides an effective treatment option for patients after progression on multiple HER2 (search)-directed therapies, used in combination with trastuzumab and capecitabine. The drug is particularly significant for patients with brain metastases (search), as it represents one of the only medications that helps slow the progression of this aggressive form of breast cancer (search).
"This drug is literally extending my life. Having it funded brings enormous financial relief to me and my family," King explained. "If the results from tucatinib continue to be favourable for me, it will allow me to go back to work and continue to be with my family."
Industry and Patient Advocacy Response
Breast Cancer Network Australia (search) (BCNA) has welcomed the PBAC recommendation, with CEO Kirsten Pilatti highlighting the impossible decisions patients have been forced to make. "These patients are deciding whether they can afford to extend their life, or literally choose not to have access to these drugs," Pilatti told media.
Vicki Durston, BCNA Director Policy, Advocacy and Support Services, emphasized the broader impact of the decision. "We consistently hear from people about the significant financial and emotional burden of accessing unfunded treatments. This decision means they will finally have equitable access to a therapy that can extend life, help manage brain metastases (search), and give families more time together."
Timeline and Implementation
The drug has been available in Australia for five years, but financial barriers have prevented widespread access. While the PBAC recommendation represents a major milestone, negotiations between the government and pharmaceutical companies are still ongoing, with no finalized date for when the PBS subsidy will take effect.
BCNA continues to work with industry and government to ensure tucatinib is listed on the PBS as soon as possible, with expectations that the listing will occur in the coming weeks.
For families like King's, the PBS listing represents more than financial relief—it offers the promise of time. "It will buy me more time with my family, which is what I really want," King said. "I want to have time to see my children growing up and see them following their dreams."